Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

Next Previous
Trial Profile

Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimivalimab (Primary) ; Vopratelimab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Concentra Biosciences; Jounce Therapeutics

Most Recent Events

  • 21 May 2024 Status changed from active, no longer recruiting to discontinued as the Sponsor decided to discontinue development of pimivalimab prior to the planned study completion. At the time of the decision to discontinue development, enrollment in the study had been completed.
  • 01 May 2024 Planned primary completion date changed from 1 Sep 2022 to 1 May 2024.
  • 29 Jun 2023 Planned End Date changed from 1 Mar 2023 to 1 May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top